Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26243
IPSCIO Record ID: 27869
Under the amended agreement, Licensor now has unilateral control over any future Prolacriaâ„¢ development and commercialization. In the event licensee resumes the Prolacriaâ„¢ clinical development program and receives regulatory approval for a Prolacriaâ„¢ product in a particular country, it will have the option to offer Prolacriaâ„¢.
Note that the actual royalty rate is from a press report and this is included at the end of the exhibit.
IPSCIO Record ID: 1449
The sale and assignment of Lotemax and Alrex.
Lotemax is a topical, site-specific steroid that is used to treat steroid responsive inflammatory eye conditions. The prescription eye drop is also used for post-operative eye inflammations such as experienced following cataract surgery. The novel chemical structure of Lotemax allows it to be predictably transformed by enzymes in the eye to an inactive metabolite, thereby increasing its safety profile.
Alrex is a specially developed formula of loteprednol etabonate that is used in the treatment of ophthalmic allergies. Alrex is indicated for the treatment of seasonal allergic conjunctivitis, an inflammation of the eye usually caused by pollens. Seasonal allergic conjunctivitis produces itching, tearing, redness and swelling in the conjunctiva, the membrane that covers the inside of the eyelid and the white part of the eye.